Annotation Detail

Information
Associated Genes
ABL2
Associated Variants
ABL2 ABL2 fusions
ABL2 ABL2 fusions
Associated Disease
Pediatric B-cell Acute Lymphoblastic Leukemia
Source Database
CIViC Evidence
Description
The ABL2-RCSD1 fusion was identified in a 5 yo boy with Ph-like B-ALL and Klinefelter syndrome. Following standard induction therapy the patient had an MRD of 1.2% in bone marrow, and continued to be MRD positive at 6 months off therapy (0.029%). He received imatinib and a bone marrow performed 2 months later showed no MRD. He maintained remission at one year post-diagnosis, on chemotherapy and imatinib. In addition, this study reports that expression of the ABL2-RCSD1 fusion protein in murine Ba/F3 cells promotes cytokine-independent proliferation and viable cells were reduced following exposure to dasatinib.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7251
Gene URL
https://civic.genome.wustl.edu/links/genes/101
Variant URL
https://civic.genome.wustl.edu/links/variants/2571
Rating
3
Evidence Type
Predictive
Disease
Pediatric B-cell Acute Lymphoblastic Leukemia
Evidence Direction
Supports
Drug
Dasatinib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
25207766
Drugs
Drug NameSensitivitySupported
DasatinibSensitivitytrue